• LGND

Ligand Pharmaceuticals executive sells $199k in stock, buys $105k

Andrew Reardon, Ligand Pharmaceuticals' CLO, sold and acquired shares per SEC regulations. The company reports strong Q2 growth, robust financial metrics, and positive market sentiment.